Cargando…
Liver Transplantation for Pediatric Liver Cancer
Unresectable hepatocellular carcinoma (HCC) was first removed successfully with total hepatectomy and liver transplantation (LT) in a child over five decades ago. Since then, children with unresectable liver cancer have benefitted greatly from LT and a confluence of several equally important endeavo...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7140094/ https://www.ncbi.nlm.nih.gov/pubmed/32204368 http://dx.doi.org/10.3390/cancers12030720 |
_version_ | 1783518918508281856 |
---|---|
author | Sindhi, Rakesh Rohan, Vinayak Bukowinski, Andrew Tadros, Sameh de Ville de Goyet, Jean Rapkin, Louis Ranganathan, Sarangarajan |
author_facet | Sindhi, Rakesh Rohan, Vinayak Bukowinski, Andrew Tadros, Sameh de Ville de Goyet, Jean Rapkin, Louis Ranganathan, Sarangarajan |
author_sort | Sindhi, Rakesh |
collection | PubMed |
description | Unresectable hepatocellular carcinoma (HCC) was first removed successfully with total hepatectomy and liver transplantation (LT) in a child over five decades ago. Since then, children with unresectable liver cancer have benefitted greatly from LT and a confluence of several equally important endeavors. Regional and trans-continental collaborations have accelerated the development and standardization of chemotherapy regimens, which provide disease control to enable LT, and also serve as a test of unresectability. In the process, tumor histology, imaging protocols, and tumor staging have also matured to better assess response and LT candidacy. Significant trends include a steady increase in the incidence of and use of LT for hepatoblastoma, and a significant improvement in survival after LT for HCC with each decade. Although LT is curative for most unresectable primary liver sarcomas, such as embryonal sarcoma, the malignant rhabdoid tumor appears relapse-prone despite chemotherapy and LT. Pediatric liver tumors remain rare, and diagnostic uncertainty in some settings can potentially delay treatment or lead to the selection of less effective chemotherapy. We review the current knowledge relevant to diagnosis, LT candidacy, and post-transplant outcomes for these tumors, emphasizing recent observations made from large registries or larger series. |
format | Online Article Text |
id | pubmed-7140094 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-71400942020-04-13 Liver Transplantation for Pediatric Liver Cancer Sindhi, Rakesh Rohan, Vinayak Bukowinski, Andrew Tadros, Sameh de Ville de Goyet, Jean Rapkin, Louis Ranganathan, Sarangarajan Cancers (Basel) Review Unresectable hepatocellular carcinoma (HCC) was first removed successfully with total hepatectomy and liver transplantation (LT) in a child over five decades ago. Since then, children with unresectable liver cancer have benefitted greatly from LT and a confluence of several equally important endeavors. Regional and trans-continental collaborations have accelerated the development and standardization of chemotherapy regimens, which provide disease control to enable LT, and also serve as a test of unresectability. In the process, tumor histology, imaging protocols, and tumor staging have also matured to better assess response and LT candidacy. Significant trends include a steady increase in the incidence of and use of LT for hepatoblastoma, and a significant improvement in survival after LT for HCC with each decade. Although LT is curative for most unresectable primary liver sarcomas, such as embryonal sarcoma, the malignant rhabdoid tumor appears relapse-prone despite chemotherapy and LT. Pediatric liver tumors remain rare, and diagnostic uncertainty in some settings can potentially delay treatment or lead to the selection of less effective chemotherapy. We review the current knowledge relevant to diagnosis, LT candidacy, and post-transplant outcomes for these tumors, emphasizing recent observations made from large registries or larger series. MDPI 2020-03-19 /pmc/articles/PMC7140094/ /pubmed/32204368 http://dx.doi.org/10.3390/cancers12030720 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Sindhi, Rakesh Rohan, Vinayak Bukowinski, Andrew Tadros, Sameh de Ville de Goyet, Jean Rapkin, Louis Ranganathan, Sarangarajan Liver Transplantation for Pediatric Liver Cancer |
title | Liver Transplantation for Pediatric Liver Cancer |
title_full | Liver Transplantation for Pediatric Liver Cancer |
title_fullStr | Liver Transplantation for Pediatric Liver Cancer |
title_full_unstemmed | Liver Transplantation for Pediatric Liver Cancer |
title_short | Liver Transplantation for Pediatric Liver Cancer |
title_sort | liver transplantation for pediatric liver cancer |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7140094/ https://www.ncbi.nlm.nih.gov/pubmed/32204368 http://dx.doi.org/10.3390/cancers12030720 |
work_keys_str_mv | AT sindhirakesh livertransplantationforpediatriclivercancer AT rohanvinayak livertransplantationforpediatriclivercancer AT bukowinskiandrew livertransplantationforpediatriclivercancer AT tadrossameh livertransplantationforpediatriclivercancer AT devilledegoyetjean livertransplantationforpediatriclivercancer AT rapkinlouis livertransplantationforpediatriclivercancer AT ranganathansarangarajan livertransplantationforpediatriclivercancer |